Biopharma AI
ByBig Pharma Accelerates Shift to Off-the-Shelf Cell Therapy with Strategic Acquisitions
The global biopharmaceutical industry is entering a new phase in cell therapy innovation, marked by significant investments in…
Drugmakers Use AI to Speed Trials and Regulatory Filings
Pharmaceutical companies are increasingly using artificial intelligence to streamline clinical trials and regulatory filings. While AI has not…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
AI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
Agentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…
